<p><strong>Strong to moderate CYP1A2 inhibitors</strong>: Coadministration may increase Riluzole-associated adverse reactions<br />
<br />
<strong>Strong to moderate CYP1A2 inducers</strong>: Coadministration may result in decreased efficacy&nbsp;<br />
<br />
<strong>Hepatotoxic drugs</strong>: Riluzole-treated patients that take other hepatotoxic drugs may be at increased risk for hepatotoxicity.</p>